UNSPSC 51282007: Bacitracin methylenedisalicylate

This classification denotes an antibiotic with the molecular formula C81H117N17O23S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGV6OJ52FT, chemically known as bacitracin methylenebis(2-hydroxybenzoate) (salt), but more generally known as bacitracin methylenedisalicylate, which bears US NIH Compound Identifier 11980094. European Medicines Agency schedules bacitracin methylenedisalicylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00652MIG.

Most nations, for tariff purposes, schedule bacitracin methylenedisalicylate under HS 29419000. SMILES:.

UNSPSC 51282007 Bacitracin methylenedisalicylate is a Commodity code for a specific topical antibiotic agent that state and local governments procure as part of broader generic and over-the-counter pharmaceutical supply agreements. The actual buying under this code occurs through multistate cooperative purchasing vehicles that bundle individual pharmaceuticals — including bacitracin methylenedisalicylate and hundreds of other products — into master supply contracts. State and local health agencies, correctional facilities, long-term care operations, and other public health entities source these products through authorized pharmaceutical wholesalers rather than directly from manufacturers. Issuing bodies include state departments of administration and multistate cooperative purchasing alliances that serve multiple state and local jurisdictions simultaneously.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota, Oregon, and other member states. Vendors must supply through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with pricing weighted 75 percent of the evaluation and fixed pricing, compliance with cGMP and DSCSA requirements, EDI capability, and agreement to a 3 percent administrative fee comprising the remainder. Products must be available by May 15, 2026, with awarded vendor agreements effective July 1, 2026. Contract terms run two years for new responders with optional extensions, or align with existing expiration dates through June 30, 2028 for incumbent responders. No set-aside restrictions were identified in the available documentation.